Alpha 2.0
Login Register
» Articles » PMID: 38991509

A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy

Overview
Journal Blood Purif
Specialty Hematology
Date 2024 Jul 11
PMID 38991509
Authors
Esha Sondhi
Martha Stewart
Jenna Harper
Leslie Konyk
Coleen McSteen
Kelli L Crowley
Nahmah Kim-Campbell
Anthony Fabio
Dana Y Fuhrman
Affiliations
Soon will be listed here.
Abstract

Introduction: Anticoagulants are used in continuous renal replacement therapy (CRRT) to prolong filter life. There are no prior investigations directly comparing epoprostenol to more commonly used forms of anticoagulation in children. Therefore, the primary aim of this study was to assess the efficacy and safety of epoprostenol as compared to heparin and citrate anticoagulation in a pediatric cohort.

Methods: We performed a retrospective analysis of all patients <18 years of age admitted to an academic quaternary care children's hospital from 2017-2022 who received epoprostenol, heparin, or citrate exclusively for CRRT anticoagulation. Efficacy was evaluated by comparing the hours to the first unintended filter change and the ratio of filters used to CRRT days. Safety was assessed by evaluating changes in platelet count and vasoactive-ionotropic score (VIS).

Results: Of 101 patients, 44 received epoprostenol (43.6%), 38 received heparin (37.6%), and 19 received citrate (18.8%). The first filter change was more commonly planned in patients receiving anticoagulation with epoprostenol (43%) as compared to citrate (11%) or heparin (29%) (p = 0.034). Of those patients where the first filter change was unintended (n = 33), there were greater median hours until the filter was replaced in those receiving epoprostenol (29) when compared to citrate (21) (p = 0.002) or heparin (18) (p = 0.003). There was a smaller median ratio of filters used to days on therapy in the patients that received epoprostenol (0.53) when compared to citrate (1) (p = 0.003) or heparin (0.75) (p = 0.001). For those receiving epoprostenol, there was no significant decrease in platelet count when comparing values prior to CRRT initiation through 7 days of therapy. There was no significant difference in VIS when comparing values prior to CRRT initiation through the first 2 days of CRRT.

Conclusions: Epoprostenol-based anticoagulation is effective when compared to other anticoagulation strategies used in pediatric CRRT with a favorable side effect profile.

References
1.
Raina R, Agrawal N, Kusumi K, Pandey A, Tibrewal A, Botsch A . A Meta-Analysis of Extracorporeal Anticoagulants in Pediatric Continuous Kidney Replacement Therapy. J Intensive Care Med. 2021; 37(5):577-594. DOI: 10.1177/0885066621992751. View
2.
Zaoral T, Hladik M, Zapletalova J, Travnicek B, Gelnarova E . Circuit Lifetime With Citrate Versus Heparin in Pediatric Continuous Venovenous Hemodialysis. Pediatr Crit Care Med. 2016; 17(9):e399-405. DOI: 10.1097/PCC.0000000000000860. View
3.
Deep A, Alexander E, Khatri A, Kumari N, Sudheendhra K, Patel P . Epoprostenol (Prostacyclin Analog) as a Sole Anticoagulant in Continuous Renal Replacement Therapy for Critically Ill Children With Liver Disease: Single-Center Retrospective Study, 2010-2019. Pediatr Crit Care Med. 2024; 25(1):15-23. PMC: 10756692. DOI: 10.1097/PCC.0000000000003371. View
4.
Buccione E, Bambi S, Rasero L, Tofani L, Piazzini T, Della Pelle C . Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review. J Clin Med. 2022; 11(11). PMC: 9181744. DOI: 10.3390/jcm11113121. View
5.
Gaies M, Gurney J, Yen A, Napoli M, Gajarski R, Ohye R . Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2009; 11(2):234-8. DOI: 10.1097/PCC.0b013e3181b806fc. View